Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers.

Authors: Afanasiev, Olga K; Yelistratova, Lola; Miller, Natalie; Nagase, Kotaro; Paulson, Kelly; Iyer, Jayasri G; Ibrani, Dafina; Koelle, David M; Nghiem, Paul

Published In Clin Cancer Res, (2013 Oct 01)

Abstract: The persistent expression of Merkel cell polyomavirus (MCPyV) oncoproteins in Merkel cell carcinoma (MCC) provides a unique opportunity to characterize immune evasion mechanisms in human cancer. We isolated MCPyV-specific T cells and determined their frequency and functional status.Multiparameter flow cytometry panels and HLA/peptide tetramers were used to identify and characterize T cells from tumors (n = 7) and blood (n = 18) of patients with MCC and control subjects (n = 10). PD-1 ligand (PD-L1) and CD8 expression within tumors were determined using mRNA profiling (n = 35) and immunohistochemistry (n = 13).MCPyV-specific CD8 T cells were detected directly ex vivo from the blood samples of 7 out of 11 (64%) patients with MCPyV-positive tumors. In contrast, 0 of 10 control subjects had detectable levels of these cells in their blood (P < 0.01). MCPyV-specific T cells in serial blood specimens increased with MCC disease progression and decreased with effective therapy. MCPyV-specific CD8 T cells and MCC-infiltrating lymphocytes expressed higher levels of therapeutically targetable PD-1 and Tim-3 inhibitory receptors compared with T cells specific to other human viruses (P < 0.01). PD-L1 was present in 9 of 13 (69%) MCCs and its expression was correlated with CD8-lymphocyte infiltration.MCC-targeting T cells expand with tumor burden and express high levels of immune checkpoint receptors PD-1 and Tim-3. Reversal of these inhibitory pathways is therefore a promising therapeutic approach for this virus-driven cancer.

PubMed ID: 23922299 Exiting the NIEHS site

MeSH Terms: Antibodies, Viral/immunology; Antigens, Viral/immunology; Antigens, Viral/metabolism; Biomarkers/metabolism; CD8-Positive T-Lymphocytes/immunology; CD8-Positive T-Lymphocytes/metabolism; Carcinoma, Merkel Cell/immunology*; Carcinoma, Merkel Cell/metabolism*; Carcinoma, Merkel Cell/pathology; Carcinoma, Merkel Cell/virology; Case-Control Studies; Hepatitis A Virus Cellular Receptor 2; Immunohistochemistry; Immunophenotyping; Lymphocytes, Tumor-Infiltrating/immunology; Lymphocytes, Tumor-Infiltrating/metabolism; Membrane Proteins/metabolism*; Merkel cell polyomavirus/immunology*; Oncogene Proteins, Viral/immunology; Oncogene Proteins, Viral/metabolism; Programmed Cell Death 1 Receptor/metabolism*; T-Lymphocyte Subsets/immunology*; T-Lymphocyte Subsets/metabolism; Tumor Burden/immunology

to Top